ABBV•benzinga•
AbbVie, Bitcoin And An Energy Stock On CNBC's 'Final Trades'
Summary
AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 15, 2024 by benzinga